licensing_iconLicensing

In addition to helping clients secure protection for their own intellectual property, BSKB represents companies looking to license intellectual property rights to others to expand markets for their goods and services or to obtain licenses from others for more freedom to sell a broader range of goods or services. BSKB also assists clients who look to cross-license intellectual property rights to create joint cooperation agreements with other companies or, as part of a more complex litigation scenario, to settle disputes with other companies.

BSKB provides legal opinions for both prospective licensors and licensees to ensure companies can move forward with licensing and acquisition plans with confidence in the value of the related intellectual property. BSKB also assists clients with an inventory and valuation of intellectual property rights and identifying and targeting potential licensing targets, as well as drafting simple to highly complex intellectual property licensing agreements.

 

Attorneys and Professionals

  • Richard Anderson

    D. Richard Anderson

    Partner

    View
  • Charles Gorenstein

    Charles Gorenstein

    Senior Counsel

    View
  • Hyuk Jung Kwon

    Hyuk Jung Kwon

    Associate

    View
  • Michael Mutter

    Michael K. Mutter

    Senior Counsel

    View
  • Jun Nakamara

    Jun (Atsushi) Nakamura

    Registered Patent Agent

    View
  • Whitney Remily

    Whitney Remily

    Of Counsel

    View

Related Articles

  • June 21, 2022

    Who Owns ‘Skin’? Kardashian’s ‘SKKN’ Facing Trademark Ambiguity

    by Kelcee Griffis | Bloomberg Law

    BSKB Partner Michael T. Smith was quoted recently in an article regarding Kim Kardashian's new skin care line, "SKKN by Kim".

  • July 1, 2022

    "Pharma Patents Under Fire From Federal Circuit, Petitions Say"

    by Samantha Handler | Bloomberg Law

    BSKB's Hailey R. Bureau, Ph.D., was quoted in an article for Bloomberg Law regarding recent rulings by the US Court of Appeals for the Federal Circuit regarding strict enforcement of certain Patent Act provisions. These rulings regarding Section 112(a), a written description requirement and an enablement standard, have created a high burden for Applicants in the life science industry to overcome.

View All Articles

Recent News

View All News

Contact Us